itraconazole
Trade name: sporanox
Approved
Sep 11, 1992
SPORANOX is the brand name for itraconazole, an azole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. SPORANOX capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary; Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. SPORANOX is also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Itraconazole is mainly metabolized through CYP3A4. Other drugs that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Similarly, itraconazole may modify the pharmacokinetics of other drugs that share this metabolic pathway. Itraconazole is a potent CYP3A4 inhibitor and a P-glycoprotein inhibitor. When using concomitant medication, it is recommended that the corresponding label be consulted for information on the route of metabolism and the possible need to adjust dosages. — NCATS
Clinical trial activity
409 trials · 246 clinical orgs · 21 marketing orgs
Earliest trial started Mar 1, 1985 (NCT00004811)
Timeline
1980s
- Jan 1, 1985
Earliest Phase 1 Sponsor(trial)
1990s
- Jan 1, 1991
Earliest Phase 2 Sponsor(trial)
- Sep 11, 1992
Johnson and Johnson — Earliest FDA Approval
- Sep 11, 1992
Johnson and Johnson — NDA Organization
- Dec 6, 1996
Johnson and Johnson — NDA Secondary Org
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
2010s
- Apr 29, 2010
Sebela Pharmaceuticals — NDA Secondary Org
- Jul 20, 2012
Mylan — Marketing Organization
- Oct 30, 2015
Amneal Pharmaceuticals — Marketing Organization
- May 26, 2016
Accord Research — Marketing Organization
- Dec 13, 2016
Alembic — Marketing Organization
- Dec 13, 2016
Par Pharmaceuticals — Marketing Organization
- Dec 13, 2016
Bristol-Myers Squibb — Marketing Organization
- Dec 13, 2016
Rising Pharmaceuticals — Marketing Organization
- Feb 23, 2017
Jubilant Innovation Ltd. — Marketing Organization
- Jun 12, 2017
Alkem Labs Ltd — Marketing Organization
- Sep 19, 2017
Zydus Discovery DMCC — Marketing Organization
- Aug 24, 2018
Torrent Pharmaceuticals Limited — Marketing Organization
- Dec 11, 2018
Mayne Pharma — NDA Secondary Org
- Dec 11, 2018
Mayne Pharma — Marketing Organization
- Jul 2, 2019
Pharmaceutics International, Inc. — Marketing Organization
- Jul 2, 2019
ANDA Repository — Marketing Organization
- Jul 2, 2019
Strides Pharma Science — Marketing Organization
- Aug 2, 2019
Apotex — Marketing Organization
2020s
- Sep 1, 2020
Annora Pharma — Marketing Organization
Indications
Approved for
Studied for
- Achlorhydria · Phase 1
- Alzheimer Disease · Phase 2
- Amyotrophic Lateral Sclerosis · Phase 1
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Phase 1
- Anxiety · Phase 2
- Arthritis, Rheumatoid · Phase 1
- Aspergillosis · Phase 4
- Aspergillosis, Allergic Bronchopulmonary · Phase 4
- Asthma · Phase 1
- Autoimmune Diseases · Phase 1
- Bacterial Infections · Phase 1
- Barrett Esophagus · Phase 2
- Basal Cell Carcinoma · Phase 2
- Biological Availability · Phase 1
- Blastomycosis · Phase 3
- Brain Neoplasms · Phase 4
- Breast Neoplasms · Phase 1
- Bronchiectasis · Phase 3
- Cachexia · Phase 1
- Candidiasis · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1
- Cardiovascular Diseases · Phase 1
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 1
- Clinical Trial, Phase I · Phase 1
- Clinical Trials, Phase I as Topic · Phase 1
- Coccidioidomycosis · Phase 2
- Contraception · Phase 1
- COVID-19 · Phase 1
- Crohn Disease · Phase 2
- Cryptococcosis · Phase 3
- Cystic Fibrosis · Phase 4
- Cytochrome P-450 Enzyme System · Phase 1
- Dermatomycoses · Phase 3
- Diabetic Foot · Early Phase 1
- Diagnostic Self Evaluation · Phase 1
- Drug Interactions · Phase 1/Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Dyslipidemias · Phase 1
- Erb-b2 Receptor Tyrosine Kinases · Phase 1
- Erectile Dysfunction · Phase 1
- Esophageal Diseases · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Febrile Neutropenia · Phase 2
- Fever · Phase 4
- Fibrosis · Phase 1
- Fungemia · Phase 3
- Glioblastoma · Phase 1
- Graft vs Host Disease · Phase 4
- Healthy Volunteers · Phase 4
- Heart Failure · Phase 1
- Heart Failure, Diastolic · Phase 1
- Hematologic Diseases · Phase 2
- Hematologic Neoplasms · Phase 4
- Hematopoietic Stem Cell Transplantation · Phase 2/Phase 3
- Hepatic Insufficiency · Phase 1
- Hepatitis B · Phase 1
- Hepatitis B, Chronic · Phase 1
- Hepatitis C, Chronic · Phase 1/Phase 2
- Histoplasmosis · Phase 3
- HIV Infections · Phase 3
- Inflammatory Bowel Diseases · Phase 2
- Invasive Fungal Infections · Phase 4
- Leukemia · Phase 1
- Leukemia, Lymphoid · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Ligaments, Articular · Phase 1
- Lung Diseases, Fungal · Phase 4
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Malaria · Phase 1
- Medical Oncology · Phase 1
- Melanoma · Phase 1
- Meningitis, Cryptococcal · Phase 2
- Mesothelioma · Phase 1
- Multiple Myeloma · Phase 1
- Multiple Sclerosis · Phase 2
- Muscular Atrophy, Spinal · Phase 1
- Mutation · Phase 1
- Mycoses · Phase 4
- Mycosis Fungoides · Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 3
- Neoplasms, Second Primary · Phase 3
- Neuralgia · Phase 1
- Neuroblastoma · Phase 4
- Neutropenia · Phase 4
- Nocturia · Phase 1
- Non-alcoholic Fatty Liver Disease · Phase 1
- Non-Smokers · Phase 1
- Obesity · Phase 1
- Onychomycosis · Phase 4
- Opioid-Related Disorders · Phase 2
- Ovarian Neoplasms · Phase 3
- Pain · Phase 1
- Pharmacokinetics · Phase 4
- Pharmacologic Actions · Phase 1
- Pharmacology, Clinical · Phase 1
- Philadelphia Chromosome · Phase 2
- Polycystic Kidney, Autosomal Dominant · Phase 1
- Primary Myelofibrosis · Phase 1
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 1
- Renal Insufficiency, Chronic · Phase 1
- Respiratory Syncytial Virus Infections · Phase 1
- Retinoblastoma · Phase 4
- Rhabdoid Tumor · Phase 1
- Rosacea · Phase 2
- Sarcoma · Phase 1
- Sarcoma, Synovial · Phase 1
- Sinusitis · Phase 2/Phase 3
- Skin Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Sporotrichosis · Phase 1/Phase 2
- Thrombosis · Phase 1
- Tinea · Phase 2/Phase 3
- Tinea Cruris · Phase 2/Phase 3
- Tinea Versicolor · Phase 4
- Tuberculosis, Pulmonary · Phase 1
- Wilms Tumor · Phase 4
- Women · Phase 1
Mechanism of action
- Cytochrome P450 14alpha-demethylaseANTAGONIST
cyp51 antagonist
- Cytochrome P450 51INHIBITOR
Cytochrome P450 51 inhibitor
Approval history
- approvedPriority reviewSep 11, 1992
Chemistry & pharmacology
SMILES
CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@H]5CO[C@@](CN6C=NC=N6)(O5)C7=CC=C(Cl)C=C7Cl)C=C4- Mol. weight
- 705.633 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- WikipediaItraconazole ↗
- NCATS304NUG5GF4 ↗
- ChEMBLCHEMBL64391 ↗
- ChEMBLCHEMBL22587 ↗
- ChEMBLCHEMBL1711 ↗
Also known as
- (alphar,betas)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1h-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
- (alphar,betas)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1h-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
- canditral
- itraconazol
- itraconazol
- itraconazole
- itraconazole
- itraconazole
- itraconazole
- itraconazole
- itraconazole
- itraconazole
- itraconazole
- itraconazole
- itraconazole
- itraconazole
- itraconazolum
- itraconazolum
- itrizole
- itrizole (tn)
- itrizole (tn)
- onmel
- onmel
- oriconazole
- oriconazole
- oriconazole
- oriconazole
- r-51211
- r-51211
- r-51211
- sporanos
- sporanos
- sporanox
- sporanox
- sporanox
- sporanox
- sporanox i.v.
- sporanox-pulse
- sporanox (tn)
- sporanox (tn)
- traconal
- triasporin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07308652 | Phase 1 | Feb 9, 2026 | Boehringer Ingelheim |
| NCT07261150 | Phase 3 | Feb 1, 2026 | Federal University of Health Science of Porto Alegre, University of Minnesota |
| NCT07283497 | Phase 4 | Dec 15, 2025 | Mayo Clinic |
| NCT07242781 | Phase 1 | Dec 8, 2025 | Bristol-Myers Squibb, Celgene |
| NCT07242703 | N/A | Dec 1, 2025 | Cairo University |
| NCT07229560 | Phase 1 | Nov 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07211425 | Phase 1 | Oct 8, 2025 | Boehringer Ingelheim |
| NCT07186452 | Phase 1 | Sep 30, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT07160738 | Phase 1 | Sep 22, 2025 | Pfizer |
| NCT07070232 | Phase 1/Phase 2 (Phase 2) | Aug 12, 2025 | Biontech |
| NCT07134465 | Phase 1 | Aug 11, 2025 | Haisco Pharmaceutical |
| NCT07069933 | Phase 2 | Jul 31, 2025 | Mansoura University |
| NCT07056842 | Phase 1 | Jul 20, 2025 | Government of China |
| NCT07018635 | Phase 1 | Jul 16, 2025 | Incyte |
| NCT07071532 | Phase 1 | Jul 15, 2025 | AbbVie |
| NCT07066722 | Phase 1 | Jul 7, 2025 | ViiV Healthcare |
| NCT06732388 | Phase 2 | Jun 2, 2025 | National Cancer Institute (NCI), University of Michigan |
| NCT06942936 | Phase 1 | May 28, 2025 | AstraZeneca, Parexel |
| NCT06945276 | Phase 1 | May 13, 2025 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06909162 | Phase 1 | May 5, 2025 | Incyte |
Organizations
Research & Development (246)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 21 | 21 | 1 | 2004 |
| Pfizer | For profit | 20 | 19 | 2 | 2006 |
| AstraZeneca | For profit | 18 | 18 | 2 | 2013 |
| Johnson and Johnson | For profit | 16 | 15 | 4 | 1999 |
| Bristol-Myers Squibb | For profit | 15 | 10 | 2 | 2014 |
| Eli Lilly | For profit | 13 | 13 | 1 | 2014 |
| Parexel | For profit | 11 | 0 | 2 | 2015 |
| Celgene | For profit | 9 | 9 | 2 | 2016 |
| Janssen Pharmaceutica NV | For profit | 9 | 4 | 4 | 1999 |
| Postgraduate Institute of Medical Education and Research | Academic/Hospital | 9 | 9 | 4 | 2010 |
| Roche | For profit | 9 | 7 | 1 | 2013 |
| Bayer | For profit | 8 | 8 | 1 | 2014 |
| GlaxoSmithKline | For profit | 8 | 6 | 2 | 2006 |
| Hengrui Therapeutics, Inc. | For profit | 8 | 8 | 1 | 2016 |
| Government of China | Government | 7 | 6 | 1 | 2020 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 7 | 6 | 3 | 1985 |
| Genentech | For profit | 6 | 6 | 1 | 2013 |
| AbbVie | For profit | 5 | 5 | 1 | 2023 |
| Astellas | For profit | 5 | 5 | 2 | 2008 |
| Enanta Pharmaceuticals | For profit | 5 | 5 | 1 | 2017 |
Marketing (26)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ANDA Repository | For profit | MKTG | Jul 2, 2019 |
| Accord Research | For profit | MKTG | May 26, 2016 |
| Alembic | For profit | MKTG | Dec 13, 2016 |
| Alembic | For profit | SYN | Dec 13, 2016 |
| Alkem Labs Ltd | For profit | MKTG | Jun 12, 2017 |
| Amneal Pharmaceuticals | For profit | MKTG | Oct 30, 2015 |
| Annora Pharma | For profit | MKTG | Sep 1, 2020 |
| Apotex | For profit | SYN | Aug 2, 2019 |
| Apotex | For profit | MKTG | Aug 2, 2019 |
| Bristol-Myers Squibb | For profit | MKTG | Dec 13, 2016 |
| Johnson and Johnson | For profit | NDA2 | Dec 6, 1996 |
| Johnson and Johnson | For profit | SYN | Sep 11, 1992 |
| Johnson and Johnson | For profit | NDA | Sep 11, 1992 |
| Jubilant Innovation Ltd. | For profit | MKTG | Feb 23, 2017 |
| Mayne Pharma | For profit | NDA2 | Dec 11, 2018 |
| Mayne Pharma | For profit | MKTG | Dec 11, 2018 |
| Mylan | For profit | MKTG | Jul 20, 2012 |
| Novartis | For profit | MKTG | May 28, 2004 |
| Par Pharmaceuticals | For profit | MKTG | Dec 13, 2016 |
| Pharmaceutics International, Inc. | For profit | MKTG | Jul 2, 2019 |
| Rising Pharmaceuticals | For profit | MKTG | Dec 13, 2016 |
| Sandoz | For profit | MKTG | May 28, 2004 |
| Sebela Pharmaceuticals | For profit | NDA2 | Apr 29, 2010 |
| Strides Pharma Science | For profit | MKTG | Jul 2, 2019 |
| Torrent Pharmaceuticals Limited | For profit | MKTG | Aug 24, 2018 |
| Zydus Discovery DMCC | For profit | MKTG | Sep 19, 2017 |